Capivasertib clinical trials
Also written AZD5363 and Truqap.
ClinicalTrials.gov finds 68 studies for capivasertib. How that becomes 55 here
Every study that search finds has been read, to see whether and how it gives capivasertib. ClinicalTrials.gov counts as of Nov 15, 2026. How drug pages count
- 68Found by its intervention search · See all 68 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 46 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- −1
Mention it without giving it — earlier treatment, a protocol code, a title naming another drug
- First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid TumorsNCT05768139 · Tersolisib, a different PI3K-alpha inhibitorReport a problem
- +1Give it under a name that search misses: a biosimilar’s code or a misspelling
- 68Give capivasertib to participants
- −2Observe patients on it, or give it outside a trial
- −2Compare another treatment with it
- −9Give it beside what is tested
- 55Test it: the count on this site
Get an email when these change. Save the capivasertib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 16 Nov 2023 · TRUQAP · NDA 218197 (FDA, Drugs@FDA)
- European Union
- 17 Jun 2024 · Truqap · EMEA/H/C/006017 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
54 studies that test it; most in 2014 (9); 1 more planned to start later
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 9 |
| 2015 | 6 |
| 2016 | 3 |
| 2017 | 1 |
| 2018 | 4 |
| 2019 | 3 |
| 2020 | 2 |
| 2021 | 7 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 4 |
| 2026 | 6 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 21 · Other 34
AstraZeneca (21) · National Cancer Institute (NCI) (3) · UNICANCER (2) · Samsung Medical Center (2) · VA Office of Research and Development (2) · Institute of Cancer Research, United Kingdom (2) · M.D. Anderson Cancer Center (1) · Velindre NHS Trust (1)
Often tested with
Tested in the same studies.
Durvalumab (6) · Olaparib (5) · Vistusertib (5) · AZD4547 (4) · Ceralasertib (4) · Osimertinib (3) · AZD 6244 (3) · Docetaxel (3)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
New treatments tested with it · 3 most studied
New when their studies opened, with capivasertib beside them; studies of each.
- 1AZD9833
- 1AMXT-1501 dicaprate
- 1IPN-60090
Reaching primary completion within a year · 6, 3 in phase 3
Studies that test capivasertib, phase 3 first.
- Dec 2026ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate CancerPhase 3 · Karolinska Institutet
- Nov 2027Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)Phase 3 · AstraZeneca
- Nov 2027A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in SpainPhase 3 · AstraZeneca
- Nov 2026A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic ImpairmentPhase 1 · AstraZeneca
- Dec 2026Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor MalignanciesPhase 1 · National University Hospital, Singapore
- Jun 2027Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate CancerPhase 2 · University of British Columbia
Studies
Open first, then newest update. How each study uses capivasertib has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 55
- Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive MeningiomasRecruitingPhase 2Alliance for Clinical Trials in OncologyNCT02523014Alone in one gene-matched meningioma armWritten as CapivasertibReport a problem
- A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN LossRecruitingPhase 2VA Office of Research and DevelopmentNCT05593497Added to hormone therapy before prostate surgeryWritten as CapivasertibReport a problem
- Immunotherapy Plus Capivasertib for Metastatic Bladder CancerNot yet recruitingPhase 1/2VA Office of Research and DevelopmentNCT07793578Added to ongoing immunotherapy in bladder cancerWritten as capivasertibReport a problem
- A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic ImpairmentRecruitingPhase 1AstraZenecaNCT07343960Single dose in moderate liver impairmentWritten as CapivasertibReport a problem
- Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA TestingNot yet recruitingPhase 3SWOG Cancer Research NetworkNCT07802626Added to standard treatment on ctDNA (SWOG)Report a problem
- Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate CancerRecruitingPhase 2University of British ColumbiaNCT04812366One biomarker-matched arm before prostate surgeryWritten as CapivasertibReport a problem
- Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based TreatmentRecruitingPhase 3Women's Cancer Study Group GmbHNCT07281833Alongside standard endocrine therapy, with quality of lifeWritten as CapivasertibReport a problem
- European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory TumorsRecruitingPhase 1/2Gustave Roussy, Cancer Campus, Grand ParisNCT02813135One arm of a paediatric precision platformWritten as CapivasertibReport a problem
- Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L OsimertinibNot yet recruitingPhase 1/2Shanxi Province Cancer HospitalNCT07486648Added to osimertinib after first-line progressionWritten as Capivasertib in combination with OsimertinibReport a problem
- CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBLRecruitingPhase 1/2University of ChicagoNCT07294677With venetoclax and low-intensity chemotherapy in ALL/LBLWritten as CapivasertibReport a problem
- HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesNot yet recruitingPhase 1/2Princess Maxima Center for Pediatric OncologyNCT07175415With venetoclax and dexamethasone in children's blood cancersWritten as CapivasertibReport a problem
- Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor MalignanciesRecruitingPhase 1National University Hospital, SingaporeNCT03772561With olaparib and durvalumab, dose findingWritten as AZD5363+Olaparib+DurvalumabReport a problem
- ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate CancerRecruitingPhase 3Karolinska InstitutetNCT03903835With docetaxel as one biomarker-assigned treatmentWritten as Capivasertib plus DocetaxelReport a problem
- Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast CancerRecruitingPhase 2GBG Forschungs GmbHNCT06607757Added to fulvestrant in high-risk lobular breast cancerWritten as CapivasertibReport a problem
- Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBCRecruitingPhase 2National Taiwan University HospitalNCT05720260Added to goserelin and fulvestrant, with or without durvalumabWritten as CapivasertibReport a problem
- Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib AloneActive, not recruitingPhase 2National Cancer Institute (NCI)NCT03660826With olaparib in one ovarian cancer armWritten as CapivasertibReport a problem
- Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT04439123In AKT1-mutant tumours (NCI-MATCH subprotocol Y)Written as CapivasertibReport a problem
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT02465060One matched subprotocol in NCI-MATCHWritten as CapivasertibReport a problem
- A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast CancerActive, not recruitingPhase 1/2AstraZenecaNCT03742102Added to durvalumab and paclitaxel in one arm (BEGONIA)Written as CapivasertibReport a problem
- A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in SpainActive, not recruitingPhase 3AstraZenecaNCT06764186With fulvestrant, a phase 3b studyWritten as CapivasertibReport a problem
See all 55 studies that test capivasertib →
Behind its US label · 1 — the studies the FDA label of TRUQAP describes
From the Clinical Studies section of TRUQAP (2026-06), as openFDA has it. A study the site does not hold is left out.
Tested on its own · 12 — no other medicine in its arm
- Immunotherapy Plus Capivasertib for Metastatic Bladder CancerNot yet recruitingPhase 1/2VA Office of Research and DevelopmentNCT07793578Added to ongoing immunotherapy in bladder cancerWritten as capivasertibReport a problem
- A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic ImpairmentRecruitingPhase 1AstraZenecaNCT07343960Single dose in moderate liver impairmentWritten as CapivasertibReport a problem
- Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based TreatmentRecruitingPhase 3Women's Cancer Study Group GmbHNCT07281833Alongside standard endocrine therapy, with quality of lifeWritten as CapivasertibReport a problem
- Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT04439123In AKT1-mutant tumours (NCI-MATCH subprotocol Y)Written as CapivasertibReport a problem
- Effect of Capivasertib on ctDNA in ER Positive Breast CancerWithdrawnPhase 2Imperial College LondonNCT06613516Its effect on blood tumour DNAWritten as CapivasertibReport a problem
- Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment SchedulesCompletedPhase 1AstraZenecaNCT01226316First-in-human, alone and with fulvestrant in some partsWritten as AZD5363Report a problem
- Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin LymphomaCompletedPhase 2AstraZenecaNCT05008055Alone in B-cell non-Hodgkin lymphomaWritten as CapivasertibReport a problem
- Study to Assess the Effect of Food and Acid Reducing Agents on the Absorption of Capivasertib in Healthy ParticipantsCompletedPhase 1AstraZenecaNCT04944771Effect of food and acid-reducing drugsWritten as CapivasertibReport a problem
- Open Label Phase I/Randomised,Double Blind Phase II Study in mCRPC of AZD5363 In Combination With DP ChemotherapyCompletedPhase 1/2University Hospital Southampton NHS Foundation TrustNCT02121639Added to docetaxel in prostate cancerWritten as AZD5363Report a problem
- AKT Inhibitor in Oestrogen Positive Breast CancerCompletedPhase 2University of NottinghamNCT02077569Short course before surgery, biomarker studyWritten as AZD5363Report a problem
- Comparison of Two Formulations of AZD5363 and the Effect of Food on Pharmacokinetic Exposure, Safety and TolerabilityCompletedPhase 1AstraZenecaNCT01895946Two formulations and the effect of foodWritten as AZD5363Report a problem
- Open Label Phase 1 Study in Japan for Patient With Advanced Solid MalignanciesCompletedPhase 1AstraZenecaNCT01353781First study in Japanese patientsWritten as AZD5363Report a problem
Tested with established drugs · 18 — they are given beside it
- CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBLRecruitingPhase 1/2University of ChicagoNCT07294677With venetoclax and low-intensity chemotherapy in ALL/LBLWritten as CapivasertibReport a problem
- Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor MalignanciesRecruitingPhase 1National University Hospital, SingaporeNCT03772561With olaparib and durvalumab, dose findingWritten as AZD5363+Olaparib+DurvalumabReport a problem
- Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast CancerRecruitingPhase 2GBG Forschungs GmbHNCT06607757Added to fulvestrant in high-risk lobular breast cancerWritten as CapivasertibReport a problem
- A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in SpainActive, not recruitingPhase 3AstraZenecaNCT06764186With fulvestrant, a phase 3b studyWritten as CapivasertibReport a problem
- Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN DeficiencyActive, not recruitingPhase 3AstraZenecaNCT04493853Added to abiraterone in hormone-sensitive prostate cancer (CAPItello-281)Written as CapivasertibReport a problem
- Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)Active, not recruitingPhase 3AstraZenecaNCT04862663Added to a CDK4/6 inhibitor and fulvestrant (CAPItello-292)Written as CapivasertibReport a problem
- Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese PatientsActive, not recruitingPhase 3AstraZenecaNCT06635447With fulvestrant after its approvalWritten as CapivasertibReport a problem
- Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast CancerActive, not recruitingPhase 3AstraZenecaNCT04305496On the US labelAdded to fulvestrant (CAPItello-291)Written as CapivasertibReport a problem
- Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBCActive, not recruitingPhase 3AstraZenecaNCT03997123Added to paclitaxel in triple-negative breast cancer (CAPItello-290)Written as CapivasertibReport a problem
- Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast CancerActive, not recruitingPhase 1/2Velindre NHS TrustNCT01992952Added to fulvestrant after an aromatase inhibitor (FAKTION)Written as AZD5363Report a problem
- PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast CancerCompletedPhase 2Queen Mary University of LondonNCT02423603Added to paclitaxel in triple-negative breast cancer (PAKT)Written as AZD5363Report a problem
- Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)Active, not recruitingPhase 3AstraZenecaNCT05348577Added to docetaxel in castration-resistant prostate cancer (CAPItello-280)Written as capivasertibReport a problem
- Trial of Olaparib in Combination with AZD5363 (ComPAKT)CompletedPhase 1Royal Marsden NHS Foundation TrustNCT02338622With olaparib, dose finding (ComPAKT)Written as AZD5363Report a problem
- AZD5363 in Patients With Advanced Solid Tumors Harboring AKT MutationsCompletedPhase 1Memorial Sloan Kettering Cancer CenterNCT03310541In AKT-mutant tumours, with hormone therapy in someWritten as AZD5363Report a problem
- A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate CancerCompletedPhase 1AstraZenecaNCT04087174Safety with enzalutamide or abirateroneWritten as CapivasertibReport a problem
- Study of AZD5363 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring PIK3CA Mutation and/or PIK3CA Amplification as a Second-line ChemotherapyCompletedPhase 2Samsung Medical CenterNCT02451956With paclitaxel in PIK3CA-altered gastric cancerWritten as AZD5363Report a problem
- Trial of AZD5363 Plus Paclitaxel /AZD2014 Plus Paclitaxel in Biomarker Negative (PIK3CA/MEK/RAS/TP53/MET) Gastric Adenocarcinoma Patients as Second-line ChemotherapyTerminatedPhase 2Samsung Medical CenterNCT02449655With paclitaxel in gastric cancer, against vistusertibWritten as AZD5363Report a problem
- A Study of Enzalutamide in Combination With AZD5363 in Patients With mCRPCStatus unknownPhase 2Institute of Cancer Research, United KingdomNCT02525068Added to enzalutamide in prostate cancerWritten as AZD5363Report a problem
Tested in a combination · 25 — another drug in the study is under test too
- Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive MeningiomasRecruitingPhase 2Alliance for Clinical Trials in OncologyNCT02523014Alone in one gene-matched meningioma armWritten as CapivasertibReport a problem
- A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN LossRecruitingPhase 2VA Office of Research and DevelopmentNCT05593497Added to hormone therapy before prostate surgeryWritten as CapivasertibReport a problem
- Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA TestingNot yet recruitingPhase 3SWOG Cancer Research NetworkNCT07802626Added to standard treatment on ctDNA (SWOG)Report a problem
- Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate CancerRecruitingPhase 2University of British ColumbiaNCT04812366One biomarker-matched arm before prostate surgeryWritten as CapivasertibReport a problem
- European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory TumorsRecruitingPhase 1/2Gustave Roussy, Cancer Campus, Grand ParisNCT02813135One arm of a paediatric precision platformWritten as CapivasertibReport a problem
- Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L OsimertinibNot yet recruitingPhase 1/2Shanxi Province Cancer HospitalNCT07486648Added to osimertinib after first-line progressionWritten as Capivasertib in combination with OsimertinibReport a problem
- HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesNot yet recruitingPhase 1/2Princess Maxima Center for Pediatric OncologyNCT07175415With venetoclax and dexamethasone in children's blood cancersWritten as CapivasertibReport a problem
- ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate CancerRecruitingPhase 3Karolinska InstitutetNCT03903835With docetaxel as one biomarker-assigned treatmentWritten as Capivasertib plus DocetaxelReport a problem
- Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBCRecruitingPhase 2National Taiwan University HospitalNCT05720260Added to goserelin and fulvestrant, with or without durvalumabWritten as CapivasertibReport a problem
- Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib AloneActive, not recruitingPhase 2National Cancer Institute (NCI)NCT03660826With olaparib in one ovarian cancer armWritten as CapivasertibReport a problem
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT02465060One matched subprotocol in NCI-MATCHWritten as CapivasertibReport a problem
- A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast CancerActive, not recruitingPhase 1/2AstraZenecaNCT03742102Added to durvalumab and paclitaxel in one arm (BEGONIA)Written as CapivasertibReport a problem
- mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and OvarianActive, not recruitingPhase 1M.D. Anderson Cancer CenterNCT02208375With olaparib in endometrial and ovarian cancerWritten as CapivasertibReport a problem
- A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Dextromethorphan (CYP2D6 Substrate) in Healthy ParticipantsCompletedPhase 1AstraZenecaNCT07241065Its effect on dextromethorphanWritten as CapivasertibReport a problem
- National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung CancerCompletedPhase 2University of BirminghamNCT02664935One matched arm in the National Lung Matrix TrialWritten as AZD5363Report a problem
- A Study to Investigate the Effect of Capivasertib on the Pharmacokinetics of Oral Rosuvastatin in Healthy ParticipantsCompletedPhase 1AstraZenecaNCT07088913Its effect on rosuvastatinWritten as CapivasertibReport a problem
- AMTEC IIT: Phase 2 Multiarm Study in TNBCTerminatedPhase 2Gordon Mills, MD, PhDNCT03801369With olaparib in one triple-negative breast cancer armWritten as CapivasertibReport a problem
- SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast CancerActive, not recruitingPhase 2UNICANCERNCT02299999One targeted maintenance option in breast cancerWritten as AZD5363Report a problem
- A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid TumoursCompletedPhase 1AstraZenecaNCT04958226Its effect on midazolamWritten as CapivasertibReport a problem
- SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC PatientsCompletedPhase 2UNICANCERNCT02117167One targeted maintenance option in lung cancerWritten as AZD5363Report a problem
Showing 20 of 25. See all 25 →
Beside a new treatment under test · 5 — a new drug, cell therapy or vaccine is what the study tests
New treatments tested with capivasertib: AZD9833 1 · AMXT-1501 dicaprate 1 · IPN-60090 1
- Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid TumorsRecruitingPhase 1/2Aminex Therapeutics, Inc.NCT07287917Standard partner of new AMXT 1501 in one cohortWritten as CapivasertibReport a problem
- IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid TumorsRecruitingPhase 1M.D. Anderson Cancer CenterNCT05039801Partner of new IACS-6274 in one partWritten as CapivasertibReport a problem
- Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.Active, not recruitingPhase 1AstraZenecaNCT03616587Partner of new camizestrant in one moduleWritten as AZD9833 with capivasertibReport a problem
- A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast CancerActive, not recruitingPhase 1AstraZenecaNCT04556773Partner of trastuzumab deruxtecan in one moduleWritten as CapivasertibReport a problem
- Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast CancerActive, not recruitingPhase 1/2Stemline Therapeutics, Inc.NCT05563220Partner of new elacestrant in one armWritten as CapivasertibReport a problem
Beside supportive care · 2 — a supportive treatment or test is studied
- Rash & Diarrhea Prophylaxis With CapivasertibRecruitingPhase 2Maryam LustbergNCT07426822In every armTreatment while rash and diarrhoea prophylaxis is testedWritten as CapivasertibReport a problem
- Fast-Her: Fasting Effects on Breast Cancer TreatmentRecruitingNot applicableUniversity of MinnesotaNCT07624617Taken throughout while fasting is testedReport a problem
One option of several · 2 — a test or a strategy chooses among drugs
- Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast CancerRecruitingPhase 1/2SynDevRx, Inc.NCT05455619One PI3K/AKT option beside new evexomostatReport a problem
- Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast CancerActive, not recruitingPhase 2University of MiamiNCT05826964One switch option guided by blood DNAReport a problem
As the comparator · 2 — what is tested is compared with capivasertib
- Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast CancerRecruitingPhase 3Relay Therapeutics, Inc.NCT06982521Comparator for new zovegalisib, both with fulvestrantWritten as CapivasertibReport a problem
- Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast CancerRecruitingPhase 2Yonsei UniversityNCT06837792One comparator option against trastuzumab deruxtecanReport a problem
Observed · 2 — patients on it are followed, or it is given outside a trial
- CAPIVASERTIB REGULATORY POSTMARKETING SURVEILLANCE IN KOREARecruitingAstraZenecaNCT06927648Post-marketing surveillance in KoreaReport a problem
- Interview of Patients With HR+/HER2- Metastatic Breast Cancer Who Received Capivasertib + FulvestrantCompletedAstraZenecaNCT07008963Patient interviews after capivasertib and fulvestrantReport a problem
Codes
What other systems call capivasertib · ClinicalTrials.gg INT006151
- MeSH (NLM) C575618capivasertibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) WFR23M21IECAPIVASERTIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27074756capivasertibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C102564CapivasertibOne source FDA
- DrugBank DB12218One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C575618 | capivasertib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | WFR23M21IE | CAPIVASERTIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27074756 | capivasertib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C102564 | Capivasertib | One source FDA |
| DrugBank | DB12218 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.